Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
Hyun Cheol ChungEsma Saada-BouzidFederico LongoEduardo YanezSeock-Ah ImEduardo CastanonDanielle N DesautelsDonna M GrahamJavier Garcia-CorbachoJuanita LopezCorina DutcusChinyere E OkparaRazi GhoriFan JinRoman GroisbergIphigenie KorakisPublished in: Cancer (2024)
The combination of lenvatinib plus pembrolizumab demonstrated antitumor activity with a manageable safety profile in patients with previously treated, advanced TNBC.
Keyphrases